Evidence map›Paper›PMID 26304077›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015

[Identification of a novel aberrant spliceosome of MPL gene (MPLL391-V392ins12)in patients with myeloproliferative neoplasms].

Ruiyuan Tian, Xiuhua Chen, Jianmei Chang, Na Zhang, Yanhong Tan, Zhifang Xu, Fanggang Ren, Junxia Zhao, Jie Pan, Haixiu Guo and 2 more

Abstract read
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruiyuan TianDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Xiuhua ChenDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Jianmei ChangDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Na ZhangDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Yanhong TanDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Zhifang XuDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Fanggang RenDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Junxia ZhaoDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Jie PanDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Haixiu GuoDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Xiaojuan WangDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Hongwei WangDepartment of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo identify the MPL L391-V392ins12 spliceosome and analyze its frequencies in patients with myeloproliferative neoplasms (MPN).

methodsMPL aberrant spliceosome was identified through reverse transcription polymerase chain reaction (RT-PCR)combined with cloning sequencing. The mutation of this spliceosome in 248 MPN patients and 200 normal people was determined by allele-specific polymerase chain reaction (AS-PCR).

resultsA novel aberrant spliceosome of MPL gene (MPL L391-V392ins12)was identified, i.e. 36 bp intron was retained between exon7 and exon8, and there were 12 amino acids (EGLKLLPADIPV)inserted. MPL L391-V392ins12 mutation was detected in 19 (7.66%)of the 248 patients with MPN, including 1 (1.92%) of 52 patients with PV, 14 (9.66%) of 145 with ET, and 4 (7.84%) of 51 with PMF. And the mutation was not detected in the group of 200 normal people.

conclusionMPL L391-V392ins12 spliceosome is an aberrant spliceosome present in the MPN. It can be detected in PV, ET and PMF, and more frequently in ET and PMF. This mutation may play an important role in the process of MPN.

Indexed as

SpliceosomesHumansMutationMyeloproliferative DisordersNeoplasmsPolymerase Chain ReactionReceptors, ThrombopoietinReceptors, Thrombopoietin

Identifiers

PMID26304077
PMCPMC7342650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.